What is TransMedics?
Headquartered in Andover, Massachusetts, TransMedics, Inc. operates at the intersection of medical device engineering and clinical transplantation. The company specializes in the development of portable warm blood perfusion systems that maintain organs in a near-physiologic state outside the human body. By mitigating the limitations of traditional cold storage, TransMedics enables surgeons to perfuse and monitor organs between donor and recipient sites, effectively expanding the pool of viable organs for transplant. This technological breakthrough positions the company as a critical player in the global healthcare landscape, addressing a significant unmet need in life-saving surgical interventions.
How much funding has TransMedics raised?
TransMedics has raised a total of $553.1M across 16 funding rounds:
Unspecified
$5.9M
Series F
$36M
Unspecified
$20M
Private Equity
$51.2M
Private Equity
$63.7M
Stock Offering
$104.7M
Stock Offering
$75M
Debt
$60M
Unspecified (2011): $5.9M featuring Undisclosed
Series F (2012): $36M backed by Abrams Capital, Hercules Capital Inc., Kleiner Perkins Caufield & Byers, and Flagship Pioneering
Unspecified (2015): $20M with participation from Undisclosed
Private Equity (2016): $51.2M led by Ervington Investments, Fayerweather Fund, Flagship Ventures, Abrams Capital, KPCB, Lung Biotechnology PBC, BioStar Capital, and InBio Ventures
Private Equity (2016): $63.7M supported by Abrams Capital, KPCB, InBio Ventures, Lung Biotechnology PBC, Ervington Investments, Fayerweather Fund, Flagship Ventures, and BioStar Capital
Stock Issuance/Offering (2019): $104.7M featuring Undisclosed
Stock Issuance/Offering (2020): $75M backed by Undisclosed
Debt (2022): $60M with participation from CIBC Innovation Banking
Key Investors in TransMedics
Kleiner Perkins
Kleiner Perkins is a Menlo Park-based venture capital firm that invests in early and growth-stage technology and life-science companies, providing capital and operational support from seed through IPO.
Flagship Pioneering
Flagship Pioneering is a company of scientists and professionals that build companies designed to transform human health and sustainability.
Abrams Capital
Abrams Capital is a value-oriented investment firm that employs an opportunistic strategy with a long-term time horizon across various asset classes and market sectors.
What's next for TransMedics?
Looking ahead, the infusion of capital from recent financing rounds provides TransMedics with the necessary liquidity to accelerate its commercial expansion and research initiatives. The company is well-positioned to leverage its established infrastructure to penetrate deeper into global markets, including Europe and Australia. Strategic priorities likely include the optimization of its OCS product suite and the pursuit of further clinical validation to solidify its market leadership. As the company transitions into its next phase of growth, the focus remains on scaling operational capacity to meet the increasing demand for advanced organ preservation solutions, ultimately driving long-term value for stakeholders and improving patient survival rates.
See full TransMedics company page
